Intercept Pharma (ICPT) Misses Q4 EPS by 48c

Intercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($2.97), $0.48 worse than the analyst estimate of ($2.49). Revenue for the quarter came in at $53.3 million versus the consensus estimate of $52.28 million.

2019 Financial Guidance

We are announcing our 2019 Ocaliva net sales guidance range of between $225 million and $240 million. In addition, we are announcing our 2019 non-GAAP adjusted operating expenses guidance range of between $450 million and $470 million, which includes expected resources to support our NASH filing and launch preparation activities. See “Non-GAAP Financial Measures” below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M